Does DTC marketing really work, and are physicians turning to AI instead of relying on MSL’s? Those are two huge questions that every pharma company faces. It depends on the category, but as AI gets smarter, I’ve found many health organizations are customizing AI access for their staff. As for DTC, the good news is it works; the bad news is that low trust in pharma makes it hard to effectively communicate with patients. The bottom line is that DTC is rapidly evolving, and so are the old methods of marketing to patients; pharma needs to build knowledge databases on what works and what is dated.
Pharma marketers love numbers. Impressions, reach, frequency, website visits, prescription lift, return on advertising investment. We can measure almost everything today, yet one of the most important questions remains surprisingly hard to answer:
Are we actually helping patients make better healthcare decisions, or are we just getting better at selling them medications? It’s a question worth asking, especially as pharmaceutical advertising becomes more expensive, consumers become more skeptical, and artificial intelligence starts changing how medical information is delivered.
Here are some statistics that should make every pharma DTC marketer rethink their strategy.
1ne. Pharma spent more than $6 billion on television advertising. Is all that spending working?
According to IQVIA, pharma companies spent more than $6 billion on direct-to-consumer television advertising in 2024, with 75 brands spending at least $10 million each. Over the previous decade, pharmaceutical television advertising approached $50 billion in cumulative spending. That’s an extraordinary amount of money, spent largely to raise patient awareness of prescription medications. But IQVIA also points to a troubling development: returns on DTC television advertising at launch are declining because of market saturation and rising costs.
Think about that for a minute. Pharma continues to invest billions in television, even as the economics of reaching and influencing consumers become increasingly challenging. How many commercials featuring happy patients walking through parks, enjoying family dinners, or playing with grandchildren can consumers watch before they all start looking alike? The problem isn’t necessarily television. It’s the assumption that spending more on awareness will automatically improve business results.
2wo. 64% Have Seen an Ad For Pharma on Social Media
A July 2025 study from NORC at the University of Chicago found that 64% of surveyed consumers had seen prescription drug advertisements on social media during the previous year. Even more interesting, 45% had encountered prescription drug content posted by social media creators.
That’s important because pharmaceutical marketing is no longer confined to traditional advertising. Patients are encountering medication information while scrolling through TikTok, Instagram, Facebook, and other platforms. Some of that information comes from pharmaceutical companies. Some comes from influencers. Some comes from patients sharing personal experiences, which may help but doesn’t necessarily reflect clinical outcomes.
For DTC marketers, this creates a difficult challenge. Consumers increasingly discover healthcare information in environments where personal stories, paid promotions, medical expertise, and misinformation compete for attention. A brand can spend millions developing carefully reviewed advertising, only to find a patient’s opinion shaped by a stranger’s 30-second video.
3hree. Sixty-nine percent of prescribers reported patients asking about drugs they saw on social media.
The same NORC research found that 69% of surveyed prescribers had patients ask about specific prescription medications encountered on social media. Of those prescribers, 61% reported prescribing the requested medication.
That strongly suggests social media is shaping conversations in physicians’ offices. But marketers need to interpret the statistic carefully. It doesn’t mean 61% of all patients who requested a drug received it, and it certainly doesn’t prove social media advertising caused every prescription.
Still, the larger point is unmistakable. Patients are arriving at medical appointments with treatment ideas already formed. The physician is no longer necessarily the first person to introduce a medication. Sometimes the physician is being asked to validate something the patient saw online.
That changes the DTC marketing equation. The objective should not simply be to generate a product request. It should ensure patients arrive with realistic expectations, understand the risks and benefits, and have questions that support an informed discussion.
4our. 70% of surveyed consumers said TV drug ads could prompt them to ask their doctor about a medication.
A Harris Poll survey commissioned by Cadent, covering more than 4,000 U.S. adults, found that approximately 70% said they were somewhat or very likely to ask a physician about a prescription medication after seeing an advertisement on traditional or connected television. The survey also found that 62% named television advertising among their top three sources for learning about medications, compared with 68% who named doctors and healthcare providers.
That’s both an opportunity and a warning. Pharmaceutical advertising has become a major source of healthcare information, nearly rivaling physicians. However, expressing an intention to ask about a medication isn’t the same as an actual conversation, a prescription, or a treatment benefit.
Marketers need to stop confusing consumer interest with meaningful patient outcomes. An advertisement that generates thousands of physician conversations may look successful on a dashboard, but what happens afterward? Were the patients clinically appropriate? Did they understand the potential adverse effects? Could they afford the medication? Did they remain on therapy?
Those are harder questions, but they’re the ones that matter.
5ive. Pharma’s digital advertising growth is accelerating, but bigger digital budgets don’t guarantee better marketing.
EMarketer projected U.S. healthcare and pharmaceutical digital advertising spending would reach $24.77 billion in 2025, a 13.3% year-over-year increase. Importantly, this is a broad healthcare and pharmaceutical advertising category, not a figure exclusively for prescription-drug DTC advertising.
The shift toward digital channels is understandable. Connected television, online video, search, and social platforms offer targeting capabilities and measurement opportunities that traditional television cannot always match. But digital precision can create an illusion of effectiveness.
A pharma brand might know how many people clicked on an advertisement, how long they stayed on a website, and whether they visited a physician-finder page. That doesn’t mean the brand understands why a patient ultimately chose a treatment, abandoned a prescription, or stopped taking medication.
Pharma needs to spend less time celebrating engagement metrics and more time understanding patient behavior. The best digital strategy isn’t necessarily the one that generates the most clicks. It’s the one that removes barriers between appropriate patients and effective treatment.
6ix. The FDA is making pharma advertising compliance a much bigger issue.
In September 2025, the FDA announced a major enforcement initiative targeting misleading prescription drug advertising, including plans to issue approximately 100 cease-and-desist letters and thousands of broader warning notices. The agency also highlighted concerns about social media influencers, AI-generated promotional content, and advertising that fails to communicate medication risks adequately.
This is more than a regulatory footnote. It should shape how pharmaceutical companies approach creative development, digital content, influencer relationships, and AI-driven personalization.
Digital marketing often tempts us to simplify everything. Shorter videos. Faster messages. Stronger claims. More compelling emotional appeals. But pharmaceutical advertising isn’t selling sneakers or smartphones. It is influencing decisions that can have serious consequences for patients.
Marketers who treat fair balance and medical accuracy as obstacles to creative execution are missing the point. In an environment where consumer trust is fragile, credible communication can become a competitive advantage.
And what about MSLs? Will artificial intelligence replace them?
This is where the pharmaceutical industry’s AI conversation gets particularly interesting. While commercial organizations are experimenting with AI-generated content, automated analytics, and increasingly sophisticated audience targeting, Medical Affairs organizations are beginning to confront a different question: If AI can summarize clinical studies, retrieve scientific evidence, analyze publications, and answer complex medical questions, how much of the traditional Medical Science Liaison role will still require a human being? The answer is more complicated than the technology vendors might want us to believe.
A global survey of 367 Medical Affairs professionals across 48 countries, published in 2026, offers some revealing statistics:
27%
Reported using AI tools for KOL engagement preparation
74%
Believe AI will have an impactful or highly impactful role in Medical Affairs
87%
Consider learning AI important or very important to remain competitive
~33%
Reported organizational policies governing MSL AI use
Source: Global cross-sectional Medical Affairs survey, 2026. Convenience sample; findings should not be treated as industry-wide adoption rates.
These numbers tell an interesting story.
Medical Affairs professionals overwhelmingly recognize that AI will change their jobs, but relatively few report using it for one of their most important responsibilities: preparing for interactions with key opinion leaders. That gap is an opportunity, but it also threatens the traditional MSL operating model.
Consider what an MSL spends time doing. They review clinical publications, prepare scientific presentations, identify relevant experts, track emerging research, answer medical questions, and document scientific exchanges. AI can already assist with many of these activities, often dramatically reducing the time required. It’s reasonable to expect that AI will automate more of this work as validated systems improve.
Here’s where the replacement argument falls apart.
An experienced MSL does more than retrieve clinical information. MSLs discuss scientific uncertainty, interpret complex evidence, recognize nuances in physician questions, understand local clinical practice, and build relationships with researchers and healthcare professionals. Those responsibilities require judgment, accountability, and trust. AI can support them, but generating a scientifically plausible answer isn’t the same as a credible scientific exchange.
A FirstWord Pharma physician survey found nearly 60% of responding doctors preferred mostly face-to-face meetings with MSLs, while almost half wanted interactions more customized to their individual needs.
That doesn’t sound like an audience ready to abandon human scientific relationships. It does, however, suggest that physicians may become less tolerant of MSL interactions that offer little beyond information they can retrieve themselves.
The real threat isn’t AI replacing MSLs. It’s AI making average MSLs less valuable.
An MSL who primarily delivers prepared slides and repeats published clinical data could become increasingly vulnerable to automation and changes in staffing models. An MSL who can engage in sophisticated scientific discussions, identify unmet research needs, challenge assumptions appropriately, and build trusted relationships with investigators offers something much harder to automate.
AI may also change Medical Affairs economics.
If an organization can use AI to reduce time spent on literature reviews, administrative documentation, and presentation development, it may reconsider territory structures, workload expectations, and how many people it needs to support particular therapeutic areas.
That could mean fewer positions in some organizations, more specialized positions in others, or simply reallocating time toward higher-value scientific engagement. Convincing evidence that AI is replacing MSLs at scale is still lacking, and predictions of widespread job elimination should be treated cautiously. The more likely near-term outcome is a hybrid model: AI handles more information-processing work while MSLs focus on interpretation, scientific dialogue, and relationships.
What DTC marketers and Medical Affairs leaders should learn from all this
A common thread runs through these developments. Pharma companies have invested enormous resources in distributing information, whether through billion-dollar advertising campaigns or highly trained scientific field teams. AI is making information easier, faster, and cheaper to produce and access. That means simply providing information is becoming less of a competitive advantage.
For DTC marketers, the challenge is to move beyond awareness and create communications that help patients understand treatment choices, navigate access barriers, and engage more effectively with healthcare professionals. For MSLs, the challenge is to move beyond delivering clinical data and demonstrate the value of expert interpretation and meaningful scientific exchange. These are distinct functions, with important regulatory boundaries between promotion and nonpromotional scientific engagement, but both face the same fundamental shift.
The future of pharmaceutical marketing and Medical Affairs won’t be determined by who can distribute the most information. It will be determined by who can make that information genuinely useful. And that raises an uncomfortable question for pharmaceutical leadership: If AI can deliver more information at a fraction of the cost, what exactly are we paying our people—and our advertising agencies—to do?
That’s the conversation the industry should be having.
Research note: The figures above come from published industry analyses and surveys released in 2025–2026, with advertising expenditure figures covering earlier periods where indicated. Survey findings describe reported behaviors or intentions, not necessarily verified prescribing outcomes.

